Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α3 subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, disease-specific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases.

Gurrieri, F., Heinzen, E., Arzimanoglou, A., Brashear, A., Clapcote, S., Goldstein, D., Joannesson, S., Mikati, M., Neville, B., Nicole, S., Ozelius, L., Poulsen, A., Schyns, T., Sweander, K., Maagdenberg, A., Vilsen, B., Distinct neurological disorders with ATP1A3 mutations., <<LANCET NEUROLOGY>>, 2014; (Maggio): 503-514. [doi:10.1016/S1474-4422(14)70011-0] [http://hdl.handle.net/10807/56838]

Distinct neurological disorders with ATP1A3 mutations.

Gurrieri, Fiorella;
2014

Abstract

Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α3 subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, disease-specific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases.
2014
Inglese
Gurrieri, F., Heinzen, E., Arzimanoglou, A., Brashear, A., Clapcote, S., Goldstein, D., Joannesson, S., Mikati, M., Neville, B., Nicole, S., Ozelius, L., Poulsen, A., Schyns, T., Sweander, K., Maagdenberg, A., Vilsen, B., Distinct neurological disorders with ATP1A3 mutations., <<LANCET NEUROLOGY>>, 2014; (Maggio): 503-514. [doi:10.1016/S1474-4422(14)70011-0] [http://hdl.handle.net/10807/56838]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/56838
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 200
  • ???jsp.display-item.citation.isi??? 189
social impact